PKPD Modeling of VEGF, sVEGFR-2, sVEGFR-3, and sKIT as Predictors of Tumor Dynamics and Overall Survival Following Sunitinib Treatment in GIST-Reference-Cited by-同舟云学术

PKPD Modeling of VEGF, sVEGFR-2, sVEGFR-3, and sKIT as Predictors of Tumor Dynamics and Overall Survival Following Sunitinib Treatment in GIST

Published:2013-11 Issue:11 Volume:2 Page:84
ISSN:2163-8306
Container-title:CPT: Pharmacometrics & Systems Pharmacology
language:en
Short-container-title:CPT: Pharmacometrics & Systems Pharmacology

Author:

Hansson EK¹,Amantea MA²,Westwood P¹,Milligan PA²,Houk BE²,French J²³,Karlsson MO¹,Friberg LE¹

Affiliation:

1. Department of Pharmaceutical Biosciences; Uppsala University; Uppsala Sweden

2. Pfizer Global Research and Development; New York New York USA

3. Metrum Research Group; Tariffville Connecticut USA

Publisher

Wiley

Subject

Pharmacology (medical),Modeling and Simulation

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1038/psp.2013.61/fullpdf

Reference36 articles.

1. Preclinical evaluation of the tyrosine kinase inhibitor SU11248 as a single agent and in combination with “standard of care” therapeutic agents for the treatment of breast cancer;Abrams;Mol. Cancer Ther,2003

2. In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship;Mendel;Clin. Cancer Res,2003

3. SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo;O'Farrell;Blood,2003

4. An orally administered multitarget tyrosine kinase inhibitor, SU11248, is a novel potent inhibitor of thyroid oncogenic RET/papillary thyroid cancer kinases;Kim;J. Clin. Endocrinol. Metab,2006

5. Predicting benefit from anti-angiogenic agents in malignancy;Jubb;Nat. Rev. Cancer,2006

Cited by 49 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Population pharmacokinetic‐pharmacodynamic modeling of serum biomarkers as predictors of tumor dynamics following lenvatinib treatment in patients with radioiodine‐refractory differentiated thyroid cancer (RR‐DTC);CPT: Pharmacometrics & Systems Pharmacology;2024-03-26

2. A PK-PD model linking biomarker dynamics to progression-free survival in patients treated with everolimus and sorafenib combination therapy, EVESOR phase I trial;Cancer Chemotherapy and Pharmacology;2023-04-03

3. A comprehensive regulatory and industry review of modeling and simulation practices in oncology clinical drug development;Journal of Pharmacokinetics and Pharmacodynamics;2023-03-04

4. Pharmacokinetic–Pharmacodynamic Modeling and Simulation in Clinical Practice and Studies;AAPS Introductions in the Pharmaceutical Sciences;2023

5. Optimization of blood pressure measurement practices for pharmacodynamic analyses of tyrosine‐kinase inhibitors;Clinical and Translational Science;2022-10-18